Introduction: In patients with severe tricuspid and pulmonary valve regurgitation and symptoms of heart failure secondary to carcinoid heart disease, valve replacement is the only effective treatment and can improve survival. Previous data on outcomes of valve replacement in carcinoid heart disease have been limited to case reports or single-centre study. Therefore we aimed to perform a nationwide database to ascertain the outcomes of tricuspid valve replacement (TVR) in carcinoid heart disease. Methodology: We utilized nationwide readmission database (NRD) to identify hospitalizations for tricuspid valve replacement in 2018. Hospitalizations with valve replacement for infective endocarditis were excluded. Characteristics and outcomes were compared between patients undergoing TVR for carcinoid versus other reasons. Multivariable logistic regression was performed to examine the predictors of in-hospital mortality after TVR. Results: A total of 1192 hospitalizations for TVR were included in the analysis of which 57 had carcinoid heart disease. There were no significant differences in short-term outcomes including in-hospital mortality (12.6% vs 11.5%, p=0.839), acute renal failure, blood transfusion, cardiogenic shock, new pacemaker insertion, length of stay and 30-day readmissions between TVR for carcinoid vs other etiologies (Table). The independent predictors of mortality in patients undergoing TVR were advanced liver disease (4.67 (2.59-8.43), p<0.001), end stage renal disease (5.09 (2.10-12.01), p<0.001), acute heart failure (2.00 (1.10-3.67), p=0.022), malnutrition (2.24 (1.13-4.31), p=0.017), and age (1.02 (1.01-1.04), p=0.020), whereas carcinoid heart disease was not an independent predictor of mortality (aOR: 1.52 (0.39-4.65), p=0.497). Conclusion: Tricuspid valve replacement in patients with carcinoid heart disease is associated with comparable short-term outcomes as for other etiologies.